These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 28366781)

  • 1. Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
    Yun S; Johnson AC; Okolo ON; Arnold SJ; McBride A; Zhang L; Baz RC; Anwer F
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):252-262. PubMed ID: 28366781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
    Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F
    Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib for the treatment of Waldenström macroglobulinemia.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel treatment options for Waldenström macroglobulinemia.
    Leblebjian H; Agarwal A; Ghobrial I
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S310-6. PubMed ID: 24290218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Waldenström macroglobulinemia in 2020.
    Castillo JJ; Treon SP
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of genomics in Waldenström macroglobulinemia.
    Branagan AR; Lei M; Treon SP; Castillo JJ
    Leuk Lymphoma; 2021 Aug; 62(8):1805-1815. PubMed ID: 33569985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
    Castillo JJ; Hunter ZR; Yang G; Treon SP
    Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current approach to Waldenström macroglobulinemia.
    Kapoor P; Rajkumar SV
    Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment options for Waldenström macroglobulinemia.
    Vijay A; Gertz MA
    Clin Lymphoma Myeloma; 2008 Aug; 8(4):219-29. PubMed ID: 18765309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
    Amaador K; Kersten MJ; Minnema MC; Vos JMI
    Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is new in the treatment of Waldenstrom macroglobulinemia?
    Castillo JJ; Treon SP
    Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 16. Toward personalized treatment in Waldenström macroglobulinemia.
    Castillo JJ; Treon SP
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):365-370. PubMed ID: 29222280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waldenström macroglobulinemia: What a hematologist needs to know.
    Kapoor P; Paludo J; Vallumsetla N; Greipp PR
    Blood Rev; 2015 Sep; 29(5):301-19. PubMed ID: 25882617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
    García-Sanz R; Tedeschi A
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A safety profile of medications used to treat Waldenström's macroglobulinemia.
    García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
    Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.